Clinical Trial SuccessThe Phase Ib update with tegoprubart shows a high probability of success for the BESTOW study, according to the KOL.
Financial StabilityManagement expects existing capital to fund operations to the end of 2026.
Safety ProfileTegoprubart is well tolerated with no cases of death, graft loss, drug-related tremor, or new-onset diabetes.